Amgen has exercised its option to obtain an exclusive worldwide license (excluding Japan) to Cytokinetics Inc.’s cardiac contractility program. The license includes CK-1827452, a cardiac myosin activator being developed for the treatment of heart failure. Under the terms of the companies’ 2006 collaboration, Amgen has agreed to pay Cytokinetics an exercise fee of $50 million and has assumed responsibility for development and commercialization of CK-1827452 and related compounds, s...